Exercise & body composition
Movement is as powerful as diet for cardiovascular health — and waist circumference predicts cardiac risk far better than weight on the scale.
Why exercise matters for cholesterol specifically
Muscle is the largest metabolic sink for glucose in the body. Skeletal muscle takes up 70–80% of glucose after a meal, in an insulin-mediated process. The more muscle you have, and the more active it is, the less glucose remains in circulation to drive hepatic de novo lipogenesis — meaning fewer triglycerides flooding into your bloodstream. This is why people with more muscle mass typically have lower TG and better insulin sensitivity, even at the same body weight.
Aerobic exercise (cardio) and resistance training do different things and both are needed. Cardio directly improves the lipid profile — published meta-analyses show consistent reductions in triglycerides (−15 to −25%), modest increases in HDL (+5 to +10%), and small reductions in LDL (−5 to −10%). Resistance training builds the muscle that does the glucose disposal long-term, and independently lowers TG and LDL by 5–15%. Doing both gives a combined effect substantially greater than either alone.
Crucially, exercise also reduces visceral adipose tissue — the metabolically dangerous fat that wraps around your organs and drives systemic inflammation, insulin resistance and dyslipidaemia. You can lose visceral fat without losing weight on the scale, because muscle mass goes up as visceral fat goes down. This is why waist circumference is a better marker than weight.
Baseline aerobic
Moderate-intensity cardio — brisk walking, cycling, swimming, hiking. UK NHS and WHO minimum. Spread across at least 5 sessions per week (avoid one big weekend session).
For meaningful lipid impact, aim for 200–300 min/week.
Zone 2 emphasis
The metabolic sweet spot. Zone 2 (low-intensity but sustained) builds mitochondrial density, improves fat oxidation, and lowers triglycerides more effectively than higher-intensity work. Talk test: you can hold a full conversation but not sing.
HR target = roughly (220 − age) × 0.65. Hit this 3-4× per week for 45-60 min.
Resistance training
Non-negotiable for muscle preservation and metabolic health. Compound movements (squats, deadlifts, presses, rows, pull-ups) recruit the most muscle. 8-12 reps per set, 3-4 sets per exercise, taken to within 2-3 reps of failure.
Even bodyweight (push-ups, lunges, planks, resistance bands) works — equipment is optional, consistency is not.
Higher intensity (high value)
HIIT / intervals at 85-95% max HR. Short bursts (30s-4min) with recovery. Boosts HDL more aggressively than steady-state cardio and improves insulin sensitivity within days.
Minute for minute, this punches well above its weight — see the panel below on why vigorous effort beats a gentle stroll. Build it on a base of Zone 2 + resistance; don't skip the base.
Post-meal walks
The most underrated cardio intervention. A short walk after each main meal flattens postprandial glucose spikes by 30-50% — directly cutting the insulin signal that drives hepatic triglyceride production.
Easier to sustain than scheduled gym sessions for many people.
Recovery & sleep
Exercise without recovery is just stress. Sleep is when muscle repair, glucose disposal optimisation, and inflammatory clearance happen. Sleep-deprived individuals have higher TG, lower HDL, and worse insulin sensitivity regardless of exercise volume.
Track resting HR — a sustained rise suggests insufficient recovery.
The intensity multiplier — why vigorous effort beats a gentle stroll
A daily walk is genuinely valuable and is the floor everyone should aim for — moving often and sitting less protects the heart on its own. But minute for minute, getting properly out of breath delivers far more cardiovascular and longevity payoff than the same time spent ambling. The official guidelines already bake this in: they count one minute of vigorous activity as worth two minutes of moderate, so 75 minutes a week of vigorous exercise earns the same credit as 150 minutes of brisk walking. The newer mortality data suggests the real gap is wider still.
*Light activity isn't counted toward the weekly target, but it still beats sitting — it's the baseline, not the goal.
How much vigorous activity actually moves the needle is surprisingly little. A large UK Biobank study using wrist trackers (Stamatakis et al., Nature Medicine, 2022) found that brief bursts of vigorous movement built into ordinary daily life — stairs taken fast, carrying heavy shopping, a sharp uphill stretch — were linked to substantially lower death rates, with most of the benefit arriving in the first few minutes a day:
of vigorous bursts woven into daily life was associated with substantially lower all-cause mortality versus none at all.
all-cause and cancer mortality, and ~32–34% lower cardiovascular mortality, at the study's median of just 4.4 min/day.
cancer and cardiovascular death linked to three short 1–2 minute vigorous bouts a day, in people who did no formal exercise.
Why intensity does this. Driving blood through the arteries fast enough generates shear stress — friction against the vessel lining — which switches on nitric-oxide production, relaxing and effectively rejuvenating the endothelium in a way gentle activity doesn't replicate. Vigorous work also raises VO₂max (cardiorespiratory fitness), which is one of the strongest modifiable predictors of mortality known: in a 122,000-patient analysis (Mandsager et al., JAMA Network Open, 2018) poor fitness carried a mortality risk on a par with — or exceeding — smoking, diabetes or hypertension. Fitness is something you can change, and intensity is how you change it fastest.
How to know if your exercise is actually doing something
You don't need a wearable or a lab test. These simple checks tell you whether the intensity, volume and consistency are at the right level for cardiometabolic benefit.
Talk test
Zone 2: you can hold a conversation but not sing. Above zone 2: speech becomes broken. This single check is more useful than HR monitoring for most people.
Sweat test
Light sweat within 10-15 minutes of starting moderate cardio means you've hit the right zone. No sweat at 20+ minutes = increase intensity.
Recovery test
You should feel better the day after exercise, not worse. Persistent fatigue or DOMS lasting 48+ hours suggests you've overshot.
Resting heart rate
A drop in resting HR over 8-12 weeks of consistent cardio (typically 5-10 bpm) confirms cardiovascular adaptation is occurring.
Stairs test
You should be able to climb 3-4 flights of stairs and hold a conversation at the top. If not, your aerobic capacity is below the threshold associated with CV protection.
Lifting progress
You should be adding small increments (more reps, more weight, harder variations) every 1-2 weeks for the first 6 months. If you're not, the stimulus isn't sufficient.
Wearable metric
Apple Watch / Garmin: aim for 30+ "exercise minutes" daily and a weekly cardio load tagged "high". Steps alone (10k/day) are useful but not enough for lipid impact.
Waist measurement
A drop in waist circumference over 8-12 weeks — even with no weight loss — is the strongest single indicator that visceral fat is reducing and metabolic health is improving.
Waist circumference matters more than weight
BMI is a poor predictor of cardiovascular risk for several reasons: it treats all weight as equal, doesn't distinguish muscle from fat, and completely misses fat distribution. Two people at the same BMI can have radically different cardiovascular risk profiles depending on where their fat sits.
Visceral fat — the deep abdominal fat that wraps your organs — is the metabolically dangerous one. It is a hormonally active tissue that secretes inflammatory cytokines, drives insulin resistance, and directly elevates triglycerides and apoB. Subcutaneous fat (under the skin, on hips and thighs) is comparatively benign. Waist circumference is a cheap, reliable proxy for visceral fat.
How to measure correctly: stand relaxed, exhale gently, measure at the midpoint between the bottom of your lowest rib and the top of your hip bone (roughly at the navel). Tape parallel to the floor, not too tight. Do it first thing in the morning before eating for consistency.
| Group | Low CV risk | Increased risk | Substantially increased |
|---|---|---|---|
| Men | < 94 cm (37") | 94–102 cm (37–40") | > 102 cm (40") |
| Women | < 80 cm (31.5") | 80–88 cm (31.5–34.5") | > 88 cm (34.5") |
| South Asian men | < 90 cm (35.5") | 90–94 cm (35.5–37") | > 94 cm (37") |
| South Asian women | < 80 cm (31.5") | 80–84 cm (31.5–33") | > 84 cm (33") |
Waist-to-height ratio — the measure NICE now asks for
There is a calculator for this if you would rather not do the arithmetic — it also gives BMI with the ethnicity-adjusted thresholds and waist-to-hip.
Waist circumference alone has an obvious flaw: 94 cm means something different on a man of 165 cm and one of 195 cm. Dividing waist by height removes that, and it is now the measure NICE asks clinicians to record alongside BMI.
| Waist ÷ height | NICE classification |
|---|---|
| 0.40–0.49 | Healthy central adiposity. No increased risk indicated by this measure |
| 0.50–0.59 | Increased central adiposity, and increased risk of type 2 diabetes, hypertension and cardiovascular disease |
| 0.60 or above | High central adiposity — a further increase in risk |
- The way to remember it is the way NICE says to explain it: keep your waist to less than half your height. A person of 180 cm is aiming for a waist under 90 cm.
- It applies across both sexes and all ethnicities, including people with high muscle mass — which is precisely where BMI fails worst. The 0.5 cut-off has held up across populations, which the sex- and ethnicity-specific waist tables above cannot claim.
- It is for adults with a BMI below 35. Above that, almost everyone has a high ratio and it stops adding information.
- It is useful even at a “healthy” BMI, which is the main reason to bother. Someone at BMI 23 with a ratio of 0.55 is carrying central fat that BMI has entirely missed.
What actually shrinks it — and why “eat less” keeps failing
Visceral fat responds well, and faster than subcutaneous fat does. The difficulty is almost never knowing what to do; it is that the standard instruction is one most people cannot sustain.
| Lever | What it does to visceral fat |
|---|---|
| Protein and fibre at every meal | The most useful single change. Both slow gastric emptying and drive satiety signalling, so people eat to comfortable fullness on less. Building the plate covers the practical version |
| Cutting drinks with calories in them | Liquid sugar barely registers as food — it does not trigger the fullness response that the same calories in solid form would, so it adds rather than displaces. The easiest single change most people can make |
| Reducing ultra-processed food | Engineered to be eaten quickly and in volume, with the fibre and structure that would slow you down removed. See eating for the heart |
| Aerobic exercise | The best-evidenced exerciser of the two for visceral fat specifically, and it works even without weight loss — which is why the tape measure moves before the scale does |
| Resistance training | Its main contribution is different and often misstated: it protects muscle while fat is being lost, which preserves the metabolic rate that makes the loss hold. Do both |
| Sleep | Short and disrupted sleep raises appetite and preferentially favours central fat. It is the lever most often ignored while the others are attempted — see sleep |
| Alcohol | Calorie-dense, appetite-raising, sleep-wrecking, and deposited centrally. See alcohol |
Epicardial fat — the depot in direct contact with the heart
Visceral fat has a subtype worth knowing about. Epicardial adipose tissue sits on the surface of the heart with no fascial barrier between it and the myocardium, sharing the same microcirculation as the coronary arteries. So the inflammatory signals it produces — interleukin-6, TNF-alpha — reach heart muscle and coronary vessels directly rather than by dilution through the whole circulation. More of it is associated with more coronary disease.
| What reduces it | Evidence |
|---|---|
| Aerobic exercise | Reduces epicardial fat, and does so even where body weight does not change — consistent with everything else on this page about the tape moving before the scale |
| Weight loss generally, including from diet | Ectopic fat depots are lost preferentially and early, which is why metabolic markers improve before much weight has gone |
| Semaglutide | In the STOP trial imaging analysis (JACC 2024), a prespecified analysis of 115 people with diabetes and known coronary disease, epicardial fat volume fell about 9% against placebo over a year, with fat density rising about 5%. Small, and an imaging endpoint rather than an outcome one — but the drug already has cardiovascular outcome evidence in its own right, so this is a candidate explanation for a benefit already established rather than a reason to take it |
| SGLT2 inhibitors | Genuinely unsettled, and often reported as though it were not. A 2026 multimodality meta-analysis (Khanna et al., International Journal of Obesity, 11 studies, 284 patients) found a significant reduction; a meta-analysis restricted to randomised trials (Diabetology & Metabolic Syndrome 2023) found no significant effect on epicardial fat specifically (standardised mean difference 0.03, confidence interval crossing zero) while the same analysis showed clear reductions in visceral, subcutaneous and liver fat. Claims that this class produces the largest reduction of anything studied are not supportable on that evidence |
| Polyphenol-rich foods | The green Mediterranean diet trials — green tea, walnuts, aquatic plants added to an otherwise similar diet — reported roughly double the visceral fat loss of a calorie-matched Mediterranean diet. Promising, from a small number of trials by overlapping groups, and measured on imaging rather than events. A reason to eat the food, not a reason to buy an extract |
How to hold this. Epicardial fat is a useful idea for understanding why central adiposity is dangerous in a way that subcutaneous fat is not — the fat is sitting on the organ, not in the hips. It is not yet a treatment target. The interventions that reduce it are the same ones already recommended for other reasons, which is reassuring rather than disappointing: nothing in this section changes what to do, and it explains rather more clearly why.
On coffee, since it comes up. Caffeine raises energy expenditure slightly and briefly. It is not a fat-loss intervention, the effect does not persist, and black coffee's real value here is that it displaces a drink with sugar in it — which is a genuine benefit and a much smaller claim than the one usually made for it.
And on the drugs. GLP-1 receptor agonists reduce visceral fat substantially, and their arrival has changed what is achievable for people in whom the above has genuinely been tried and has not worked. They are a legitimate option rather than a failure of willpower — and they are a second-line one, because the levers above improve cardiovascular risk through routes that weight loss alone does not, and because stopping the drug generally returns the weight. Related evidence is in the fatty liver chapter, where the same drug class has a conditional authorisation.
The important framing is that this is an access advance, not an efficacy one. In ATTAIN-1, 3,127 adults without diabetes lost 7.5% to 11.2% of body weight at 72 weeks against 2.1% on placebo, dose-dependent. That sits below the injectable agents — roughly 15% for semaglutide and 21% for tirzepatide in their own pivotal trials, which is a cross-trial comparison rather than a head-to-head, and a gap the manufacturer concedes. Both of those injectables are already available in the UK. So the British reader is not missing the more effective drug; they are missing the more convenient one. It carries the same boxed warning about thyroid C-cell tumours as the rest of the class.
And you will meet a bigger number, so here is why the two differ. The label and the manufacturer's launch material headline 12.4% at the top dose. That is the efficacy estimand — what happened in people who stayed on treatment. The 11.2% quoted above is the treatment-regimen estimand, which counts everyone as randomised including those who stopped. Neither is wrong; the second is the more conservative and the more useful for deciding whether to start, because in real life some people stop. A page quoting only one of them looks wrong to anyone who has seen the other.
One thing NICE says about this that is easy to skip, and worth not skipping. The guidance asks clinicians to seek permission before raising weight or central adiposity and before taking measurements, and to respect a refusal without judgement. That is a formal recommendation rather than a courtesy — and if you are measuring yourself, the same logic applies in a different direction: this is a number to act on, not a number to feel bad about.